A Study to Evaluate the Safety, Tolerability, and Drug Levels of MYK-224 Administered in Single and Multiple Doses in Healthy Adult Japanese Participants
Trial Summary
Will I have to stop taking my current medications?
The trial is for healthy participants without any acute or chronic medical illnesses, so it seems likely that you should not be on any current medications. However, the protocol does not specify this explicitly.
What evidence supports the effectiveness of the drug MYK-224?
Is the treatment MYK-224 generally safe for humans?
How does the drug MYK-224 differ from other treatments for cancer?
What is the purpose of this trial?
This trial is testing a new drug called MYK-224 in healthy adult Japanese participants to see how different doses affect them.
Research Team
Bristol-Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Eligibility Criteria
Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive single and multiple doses of MYK-224 to evaluate safety, tolerability, and pharmacokinetics
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- MYK-224
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Bristol-Myers Squibb
Lead Sponsor
Christopher Boerner
Bristol-Myers Squibb
Chief Executive Officer since 2023
PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis
Deepak L. Bhatt
Bristol-Myers Squibb
Chief Medical Officer since 2024
MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania